TORC1 inhibition enhances immune function and reduces infections in the elderly

Area of Science:

• Gerontology
• Immunology
• Pharmacology

Background:

• Mechanistic target of rapamycin (mTOR) inhibition shows promise in extending lifespan and improving age-related conditions in model organisms.
• Aging is associated with declining immune function and increased susceptibility to infections.
• Targeting mTOR may offer a therapeutic strategy to counteract age-related immune senescence.

Purpose of the Study:

• To evaluate the safety and efficacy of a low-dose mTOR inhibitor combination therapy in elderly subjects.
• To determine if mTOR inhibition enhances immune function and reduces infection rates in the elderly.
• To assess the impact of selective TORC1 inhibition on antiviral gene expression and vaccine response.

Main Methods:

• Phase 2a, randomized, placebo-controlled clinical trial involving 264 elderly subjects.
• Administration of a low-dose combination of catalytic (BEZ235) and allosteric (RAD001) mTOR inhibitors for 6 weeks.
• Monitoring of infection rates, immune function, gene expression, and influenza vaccine response over one year.

Main Results:

• The low-dose mTOR inhibitor combination was safe and well-tolerated in elderly subjects.
• A significant decrease (P = 0.001) in reported infection rates was observed in the treatment group.
• Up-regulation of antiviral gene expression and improved response to influenza vaccination were noted.

Conclusions:

• Selective inhibition of target of rapamycin complex 1 (TORC1) using a combination of BEZ235 and RAD001 is safe in the elderly.
• This therapeutic approach has the potential to enhance immune function and reduce infection incidence in older adults.
• mTOR inhibition represents a promising strategy for improving healthspan and combating age-related immune decline.